Definition: Barbiturates are white crystalline substances with a bitter taste. They are derivatives of barbituric acid.
Long Acting (Duration: -24 hrs)
Examples: Barbitone, Phenobarbitone, Methyl phenobarbitone, Butobarbitone
Intermediate Acting (Duration: 3-6 hrs)
Examples: Amylobarbitone, Allobarbitone
Short Acting (Duration: <3 hrs)
Examples: Cyclobarbitone, Hexabarbitone, Pentobarbitone
Ultra Short Acting (Duration: 5-10 minutes)
Examples: Pentothal sodium (thiopentone sodium), Methohexobarbitone
Absorption: Rapidly absorbed from the gastrointestinal tract; faster with alcohol.
Administration: Immediate onset with intravenous (i.v.) or intramuscular (i.m.) administration.
Distribution: Concentrated in the liver, brain, and kidneys. Metabolized in the liver to mostly inactive, water-soluble metabolites.
Excretion: A small amount excreted unchanged in urine.
CNS Effects: Depresses central nervous system (CNS) activity.
GABA Interaction: Acts at GABA receptors, increasing chloride ion channel duration, enhancing inhibitory effects.
Nerve Transmission: At high concentrations, increases chloride conductance and inhibits neurotransmitter release.
Cell Excitability: Decreases excitability of CNS cells; large doses can depress respiratory and vasomotor centers.
Metabolism: Basal metabolism and intestinal mobility reduced; inhibits diuresis.
Synergistic Action: Has enhanced effects when combined with alcohol.
CNS:
Drowsiness, confusion, ataxia, slurred speech, headache, excitement.
May progress to stupor, deep coma, unresponsive to pain, and a positive Babinski's sign.
Pupil reaction alters from constricted to dilated and non-reactive.
Respiratory System:
Respiratory depression leading to shallow, labored breathing; Cheyne-Stokes respiration may occur.
Risk of hypostatic pneumonia after prolonged survival.
Cardiovascular System (CVS):
Decreased cardiac output, increased capillary permeability, potential for cardiovascular collapse; possible cyanosis and hypotension.
ECG may show slow waves during severe intoxication.
Skin:
Blisters may appear due to toxic effects on the epidermis and tissue anoxia(anoxic bullae), especially at pressure points.
Affects areas like axilla, inter-digital clefts, inner aspects of knees and buttocks.
Associated Conditions:
Leucopenia and thrombocytopenia may occur.
Body temperature is reduced; peristaltic movements decreased.
Death primarily due to respiratory paralysis; faster with higher doses.
Short Acting: Fatal Dose 1-2g; Treatment 2-3g
Medium Acting: 3-5g; Blood level 7 mg%
Long Acting: Fatal Dose 10g; Blood level 10 mg%
Generally: 1-2 days; massive doses can lead to death within hours.
Maintain airway and provide adequate respiratory support.
Administer artificial respiration and oxygen to prevent hypoxia.
Conduct stomach wash with 1:1000 KMnO4 if conscious; endotracheal intubation if unconscious.
Give activated charcoal.
Prophylactic antibiotics to prevent pneumonia.
Administer intravenous fluids for fluid and electrolyte balance.
The above 6 methods are called Scandinavian method
Implement Forced Alkaline Diuresis for drugs like phenobarbitone.
Alkalinisation of urine with sodium bicarbonate; maintain urinary pH 7.5-8.
Consider hemodialysis.
Exchange transfusion may be life-saving.
Provide symptomatic treatment as necessary.
Rapid Death: Generalized congestion of internal organs, edema of lungs and brain.
Delayed Death: Bullous lesions, pneumonic consolidation, softening of corpus callosum, globus pallidus, and cerebral focal areas.
Chronic Poisoning: Frequent in suicidal attempts; rare in homicide.
Accidental Poisoning: Can arise from 'drug automatism'.
Addiction Potential: Psychological and physical dependence with tolerance, which resolves within 2-3 days post-withdrawal.
Resembles symptoms of chronic alcoholism:
Memory loss, dysarthria, ataxia, depression, Parkinsonian tremors, impaired intellectual function and behavior.
Withdrawal Symptoms appear within a day and may persist for 2 weeks: anxiety, nausea, vomiting, tremors, restlessness, hypotension, potential convulsions.